Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

L. Kiemeney | L. Andrews | R. Eeles | Z. Kote-Jarai | F. Hamdy | W. Foulkes | A. Ardern-Jones | E. Page | D. Dearnaley | V. Khoo | G. Rennert | S. Buys | A. Vickers | D. Eccles | D. Evans | N. Aaronson | B. Helfand | H. Gronberg | M. Longmuir | D. Halliday | H. Lilja | M. Adank | R. Schmutzler | J. Lubiński | S. Teo | M. Brook | C. V. van Asperen | A. Spigelman | J. Kirk | E. Friedman | P. Cooke | D. Murphy | S. Domchek | J. Eyfjord | J. Oosterwijk | O. Johannsson | R. Oldenburg | B. Arun | J. McGrath | T. Ramón Y Cajal | N. Pachter | L. Side | G. Lindeman | P. James | D. Rosario | M. Ausems | J. Powers | C. Moynihan | H. Vasen | N. Nicolai | C. Foster | C. Cybulski | D. Wokołorczyk | M. Teixeira | H. Hanson | A. Brady | Penny Wilson | M. Tischkowitz | K. Kast | K. Rhiem | J. Offman | C. Bangma | A. Aprikian | T. Dudderidge | Sarah Thomas | L. Greenhalgh | L. Feliubadaló | E. Bancroft | E. Obeid | A. Mitra | L. Izatt | W. V. van Zelst-Stams | T. V. van Os | C. Brewer | R. Davidson | A. Henderson | M. Suri | S. Carlsson | J. Cook | A. Donaldson | J. Barwell | A. Falconer | L. Maehle | E. Grindedal | Marta Cardoso | D. Gallagher | K. Ong | K. Snape | L. Walker | Munaza Ahmed | M. Harris | V. Murthy | A. Liljegren | K. O’toole | J. Zgajnar | S. Saya | N. Taylor | J. Rothwell | A. Dias | C. Mikropoulos | Jenny Pope | A. Chamberlain | R. Chen-Shtoyerman | K. Axcrona | K. Shackleton | M. Salinas | K. Tricker | R. Susman | Thomas Jensen | E. Castro | J. McKinley | M. Ruijs | V. Stefansdottir | Amy Taylor | P. Osther | M. Assel | L. Mascarenhas | C. Morton | N. Gadea | Rachel Williams | Camilla Huber | T. Thomas | L. Copáková | H. N. Raghallaigh | J. Ringelberg | E. Genova | Jimmy Lam | Louise Taylor | V. Tripathi | A. Azzabi | I. Jobson | Karina Rønlund | Kate Richardson | Mona Hassan Al Battat | Heleen van Randeraad | Apollonia T J M Helderman van den Enden | A. Ardern-jones | D. Evans | J. Cook | M. Ahmed | D. Evans | D. Evans | E. Friedman | M. Teixeira | Mónica Salinas | D. Evans | Vigdis Stefansdottir | T. Ramón y Cajal

[1]  W. Chung,et al.  Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). , 2020, JAMA oncology.

[2]  Arjun K Menta,et al.  Cancer Genetics and Therapeutic Opportunities in Urologic Practice , 2020, Cancers.

[3]  Alexandra O. Sokolova,et al.  Genetic Testing in Prostate Cancer , 2020, Current Oncology Reports.

[4]  Jianfeng Xu,et al.  Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. , 2019, European urology.

[5]  T. H. van der Kwast,et al.  Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. , 2019, Urologic oncology.

[6]  Rhian Gabe,et al.  Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. , 2018, Health technology assessment.

[7]  J. Sterne,et al.  Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.

[8]  L. Kiemeney,et al.  University of Southern Denmark Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition , 2018 .

[9]  J. Hugosson,et al.  Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality , 2018, Scandinavian journal of urology.

[10]  Martin Eklund,et al.  The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing. , 2016, European urology focus.

[11]  T. Tammela,et al.  A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. , 2017, European urology focus.

[12]  D. Steinemann,et al.  Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores , 2017, Journal of Clinical Oncology.

[13]  G. Andriole,et al.  Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4‐Kallikrein Marker Panel , 2017, The Journal of urology.

[14]  Takafumi N. Yamaguchi,et al.  Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories , 2017, Nature Communications.

[15]  S. Friedman,et al.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  J. Gohagan,et al.  Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up. , 2016, Gynecologic oncology.

[17]  David Atkinson,et al.  INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer , 2016, BMC Cancer.

[18]  V. Laudone,et al.  Variation in serum prostate‐specific antigen levels in men with prostate cancer managed with active surveillance , 2016, BJU international.

[19]  D. Nieboer,et al.  Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort , 2016, BJU international.

[20]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[21]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[22]  L. Kiemeney,et al.  Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study , 2014, European urology.

[23]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Easton,et al.  Germline BRCA1 mutations increase prostate cancer risk , 2012, British Journal of Cancer.

[25]  D. Easton,et al.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients , 2011, British Journal of Cancer.

[26]  S. Fox,et al.  The Dawn of a Revolution in Personalized Lung Cancer Prevention , 2011, Cancer Prevention Research.

[27]  Katherine M. Tucker,et al.  Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study , 2011, BJU international.

[28]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[29]  R. Eeles,et al.  Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype , 2008, British Journal of Cancer.

[30]  Thorunn Rafnar,et al.  Prostate cancer progression and survival in BRCA2 mutation carriers. , 2007, Journal of the National Cancer Institute.

[31]  R. Eeles,et al.  A review of targeted screening for prostate cancer: introducing the IMPACT Study , 2007, BJU international.

[32]  D. Jewell,et al.  Genotype-phenotype analysis of the Crohn’s disease susceptibility haplotype on chromosome 5q31 , 2003, Gut.

[33]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[34]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.